MyFinsight
Home
Blog
About
Proceeds from sale of prv,
net
$178,190K
Proceeds from maturities
of investments
$51,000K
(-69.42%↓ Y/Y)
Issuance of common stock
pursuant to exercise of...
$152K
Net cash provided by
(used in) investing...
$214,360K
(915.86%↑ Y/Y)
Net cash provided by
financing activities
$150K
(-30.23%↓ Y/Y)
Canceled cashflow
$14,830K
Canceled cashflow
$2K
Net change in cash,
cash equivalents and...
$174,897K
(233.70%↑ Y/Y)
Canceled cashflow
$39,613K
Purchases of investments
$14,822K
(-92.31%↓ Y/Y)
Purchases of property and
equipment
$8K
(-98.07%↓ Y/Y)
Net income (loss)
$123,214K
(194.60%↑ Y/Y)
something is missing
$11,498K
Stock-based compensation
$7,419K
(-64.98%↓ Y/Y)
Depreciation and
amortization of property and...
$1,564K
(-65.17%↓ Y/Y)
Amortization of finance lease
right of use asset
$539K
(-49.95%↓ Y/Y)
Other liabilities
$67K
(183.75%↑ Y/Y)
Finance lease liability
$2K
(-92.00%↓ Y/Y)
Net cash used in
operating activities
-$39,613K
(62.18%↑ Y/Y)
Canceled cashflow
$144,301K
Gain from sale of prv,
net
$178,190K
Accounts payable and
accrued expenses
$4,699K
(64.13%↑ Y/Y)
Accretion of discount on
investments, net
$643K
(-85.00%↓ Y/Y)
Prepaid expenses and
other assets
$355K
(277.50%↑ Y/Y)
Operating lease
liabilities and right of use...
-$27K
(-222.73%↓ Y/Y)
Back
Back
Cash Flow
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)
source: myfinsight.com